◎ Sugi Atlas

Atlas / Disease / Eosinophilic esophagitis

Eosinophilic esophagitis

disease
On this page

Also known as EoE

Summary

Eosinophilic esophagitis (MONDO:0005361) is a disease with 37 cohort genes (124 GWAS associations across 9 studies) and 207 clinical trials. The dominant Reactome pathway is Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells) (3 cohort genes). Top therapeutic interventions include dupilumab, budesonide, and fluticasone propionate.

At a glance

  • Cohort genes: 37
  • GWAS associations: 124
  • Clinical trials: 207

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameeosinophilic esophagitis
Mondo IDMONDO:0005361
EFOEFO:0004232
MeSHD057765
Orphanet73247
DOIDDOID:13922
ICD-10-CMK20.0
NCITC27105
SNOMED CT235599003
UMLSC0341106
MedGen83318
GARD0027720
MedDRA10064212
Is cancer (heuristic)no

Also known as: EoE

Data availability: 124 GWAS associations (9 studies).

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › upper digestive tract disorder › esophageal disorder › esophagitis › eosinophilic esophagitis

Related subtypes (5): fungal esophagitis, bacterial esophagitis, viral esophagitis, peptic esophagitis, Crohn disease of the esophagus

Subtypes (3): childhood eosinophilic esophagitis, esophagitis, eosinophilic, 1, esophagitis, eosinophilic, 2

Genetics & variants

GWAS landscape

124 GWAS associations across 9 studies. Top hits map to 34 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs171317262e-27DDAH1?
rs14386736e-22WDR36 - RPS3AP21C0.7
rs1434573893e-16PRKD3A1.77
rs1434573883e-16CAPN14A1.77
rs618945475e-15EMSYT1.79
rs2527164e-14TSLP - WDR36C1.52
rs350990842e-12CLEC16AT0.72
rs22792935e-11RORAG0.69
rs775698593e-10CAPN14G1.98
rs8879924e-10TMEM182C0.75
rs560621354e-10SMAD3T1.29
rs1498647955e-10CAPN14A2.22
rs80412276e-10LINC03034 - KLF13G1.52
rs1821396151e-09SHANK2T6.62
rs38157002e-09ANKRD27C1.62
rs38069323e-09BCLAF1P1 - TSLP?1.85
rs5997073e-09SNHG32 - NEU1?1.69
rs1460344993e-09WASF3 - GPR12A5.92
rs25138457e-09MATN2T4.18
rs1884836549e-09URGCP-MRPS24, URGCPC5.68
rs1473070361e-08LARP1BP2 - CTB-30L5.1A8.04
rs1858116021e-08PRKG1, PRKG1-AS1T6.37
rs1477020041e-08RHOG - STIM1-AS1T1.95
rs3719152e-08MEAK7?1.9
rs38069332e-08TSLPG1.37
rs5348454652e-08INO80C - GALNT1A5.78
rs16209963e-08BOLA2P3T0.69
rs625415564e-08JAK2T1.61
rs1910512384e-08CCNYC13.2
rs5543188374e-08CPNE4C2.88

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90027899Chang X20211,93013,634A genome-wide association meta-analysis identifies new Eosinophilic esophagitis loci.
GCST012381Chang X20211,2886,548A genome-wide association meta-analysis identifies new Eosinophilic esophagitis loci.
GCST009070Kottyan LC20181,2103,734Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitis.
GCST90482132Verma A2024756450,273Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST002527Kottyan LC20146579,296Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.
GCST002697Sleiman PM20146033,637GWAS identifies four novel eosinophilic esophagitis loci.
GCST012380Chang X20215427,146A genome-wide association meta-analysis identifies new Eosinophilic esophagitis loci.
GCST000620Rothenberg ME20101811,974Common variants at 5q22 associate with pediatric eosinophilic esophagitis.
GCST90270131Gautam Y20221371,465Genome-wide admixture and association analysis identifies African ancestry specific risk loci of eosinophilic esophagitis in African American.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding3
Tier 2: splice/UTR1
Tier 3: regulatory3
Tier 4: intronic/intergenic43

MAF distribution

BucketVariants
common (>=0.05)27
low_freq (0.01-0.05)11
rare (<0.01)9
unknown3

Functional consequences

ConsequenceCount
intron_variant29
intergenic_variant11
non_coding_transcript_exon_variant3
regulatory_region_variant3
missense_variant3
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs17131726185520457A>Gintron_variantDDAH12e-27Tier 4: intronic/intergenic
rs14386735111131801C>A,G,T0.498intergenic_variantWDR36 - RPS3AP216e-22Tier 4: intronic/intergenic
rs143457389237301765T>C0.046intron_variantPRKD33e-16Tier 4: intronic/intergenic
rs143457388231179504T>A,G0.047intron_variantCAPN143e-16Tier 4: intronic/intergenic
rs618945471176537586C>G,T0.04intron_variantEMSY5e-15Tier 4: intronic/intergenic
rs2527165111089365G>A,C,T0.447intron_variantTSLP - WDR364e-14Tier 4: intronic/intergenic
rs350990841611095760C>G,T0.22intron_variantCLEC16A2e-12Tier 4: intronic/intergenic
rs22792931560765158C>G,T0.145non_coding_transcript_exon_variantRORA5e-11Tier 4: intronic/intergenic
rs77569859231188421T>C,G0.05intron_variantCAPN143e-10Tier 4: intronic/intergenic
rs8879922102908473C>A,T0.362intergenic_variantTMEM1824e-10Tier 4: intronic/intergenic
rs560621351567163292C>T0.228intron_variantSMAD34e-10Tier 4: intronic/intergenic
rs149864795231179541G>A0.052intron_variantCAPN145e-10Tier 4: intronic/intergenic
rs80412271531246339G>A0.28intergenic_variantLINC03034 - KLF136e-10Tier 4: intronic/intergenic
rs1821396151170682745C>T0.001intron_variantSHANK21e-09Tier 4: intronic/intergenic
rs38157001932602346T>A,C,G0.14intron_variantANKRD272e-09Tier 4: intronic/intergenic
rs38069325111069977A>G0.46regulatory_region_variantBCLAF1P1 - TSLP3e-09Tier 3: regulatory
rs599707631840659C>G,T0.114intergenic_variantSNHG32 - NEU13e-09Tier 4: intronic/intergenic
rs1460344991326752208G>A,C0.001intergenic_variantWASF3 - GPR123e-09Tier 4: intronic/intergenic
rs2513845897941784T>A,C0.003missense_variantMATN27e-09Tier 1: coding
rs188483654743894035T>C0.002intron_variantURGCP-MRPS24, URGCP9e-09Tier 4: intronic/intergenic
rs1473070367106409865C>A,T0.003intron_variantLARP1BP2 - CTB-30L5.11e-08Tier 4: intronic/intergenic
rs1858116021052207157A>T0.001non_coding_transcript_exon_variantPRKG1, PRKG1-AS11e-08Tier 4: intronic/intergenic
rs147702004113844266A>T0.018intergenic_variantRHOG - STIM1-AS11e-08Tier 4: intronic/intergenic
rs3719151684544635A>C,G,T0.13regulatory_region_variantMEAK72e-08Tier 3: regulatory
rs38069335111071044C>A,T0.44regulatory_region_variantTSLP2e-08Tier 3: regulatory
rs5348454651835558053G>A0.002intergenic_variantINO80C - GALNT12e-08Tier 4: intronic/intergenic
rs1620996621602321T>C0.117non_coding_transcript_exon_variantBOLA2P33e-08Tier 4: intronic/intergenic
rs6254155695049092G>A,T0.251intron_variantJAK24e-08Tier 4: intronic/intergenic
rs1910512381035530442G>C0.001intron_variantCCNY4e-08Tier 4: intronic/intergenic
rs5543188373132064434A>C0.008intergenic_variantCPNE44e-08Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 23 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RORAOrphanet:528084Non-specific syndromic intellectual disability
SOX4Orphanet:1465Coffin-Siris syndrome
STAT6Orphanet:2126Solitary fibrous tumor
SLC25A24Orphanet:2095Gorlin-Chaudhry-Moss syndrome
SLC25A24Orphanet:2963Progeroid syndrome, Petty type
JAZF1Orphanet:213711Endometrial stromal sarcoma
JAZF1Orphanet:536Systemic lupus erythematosus
DSG1Orphanet:369992Severe dermatitis-multiple allergies-metabolic wasting syndrome
DSG1Orphanet:369999Diffuse palmoplantar keratoderma with painful fissures
DSG1Orphanet:370002Focal palmoplantar keratoderma with joint keratoses
DSG1Orphanet:50942Striate palmoplantar keratoderma
JAK2Orphanet:131Budd-Chiari syndrome
JAK2Orphanet:3318Essential thrombocythemia
JAK2Orphanet:667662Breast implant-associated anaplastic large cell lymphoma
JAK2Orphanet:71493Familial thrombocytosis
JAK2Orphanet:729Polycythemia vera
JAK2Orphanet:824Primary myelofibrosis
SMAD3Orphanet:284984Aneurysm-osteoarthritis syndrome
SMAD3Orphanet:60030Loeys-Dietz syndrome
SMAD3Orphanet:91387Familial thoracic aortic aneurysm and aortic dissection
PRKG1Orphanet:91387Familial thoracic aortic aneurysm and aortic dissection
RAD50Orphanet:145Hereditary breast and/or ovarian cancer syndrome
RAD50Orphanet:240760Nijmegen breakage syndrome-like disorder

Cohort genes → proteins

37 cohort genes, 35 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only37

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RORAHGNC:10258ENSG00000069667P35398Nuclear receptor ROR-alphagwas
SEMA6AHGNC:10738ENSG00000092421Q9H2E6Semaphorin-6Agwas
SOX4HGNC:11200ENSG00000124766Q06945Transcription factor SOX-4gwas
STAT6HGNC:11368ENSG00000166888P42226Signal transducer and activator of transcription 6gwas
DEXIHGNC:13267ENSG00000182108O95424Dexamethasone-induced proteingwas
KLF13HGNC:13672ENSG00000169926Q9Y2Y9Krueppel-like factor 13gwas
SHANK2HGNC:14295ENSG00000162105Q9UPX8SH3 and multiple ankyrin repeat domains protein 2gwas
CAPN14HGNC:16664ENSG00000214711A8MX76Calpain-14gwas
EMSYHGNC:18071ENSG00000158636Q7Z589BRCA2-interacting transcriptional repressor EMSYgwas
SNHG32HGNC:19078ENSG00000204387small nucleolar RNA host gene 32gwas
SLC25A24HGNC:20662ENSG00000085491Q6NUK1Mitochondrial adenyl nucleotide antiporter SLC25A24gwas
CPNE4HGNC:2317ENSG00000196353Q96A23Copine-4gwas
CCNYHGNC:23354ENSG00000108100Q8ND76Cyclin-Ygwas
ANKRD27HGNC:25310ENSG00000105186Q96NW4Ankyrin repeat domain-containing protein 27gwas
CCDC81HGNC:26281ENSG00000149201Q6ZN84Coiled-coil domain-containing protein 81gwas
TMEM182HGNC:26391ENSG00000170417Q6ZP80Transmembrane protein 182gwas
XKR6HGNC:27806ENSG00000171044Q5GH73XK-related protein 6gwas
JAZF1HGNC:28917ENSG00000153814Q86VZ6Juxtaposed with another zinc finger protein 1gwas
CLEC16AHGNC:29013ENSG00000038532Q2KHT3Protein CLEC16Agwas
NAMPTHGNC:30092ENSG00000105835P43490Nicotinamide phosphoribosyltransferasegwas
DSG1HGNC:3048ENSG00000134760Q02413Desmoglein-1gwas
WDR36HGNC:30696ENSG00000134987Q8NI36WD repeat-containing protein 36gwas
TSLPHGNC:30743ENSG00000145777Q969D9Thymic stromal lymphopoietingwas
URGCPHGNC:30890ENSG00000106608Q8TCY9Up-regulator of cell proliferationgwas
GALNT1HGNC:4123ENSG00000141429Q10472Polypeptide N-acetylgalactosaminyltransferase 1gwas
LRRC32HGNC:4161ENSG00000137507Q14392Transforming growth factor beta activator LRRC32gwas
MIR4675HGNC:41619ENSG00000265372microRNA 4675gwas
GPR12HGNC:4466ENSG00000132975P47775G-protein coupled receptor 12gwas
HSF2BPHGNC:5226ENSG00000160207O75031Heat shock factor 2-binding proteingwas
HSPA1BHGNC:5233ENSG00000204388P0DMV9Heat shock 70 kDa protein 1Bgwas
JAK2HGNC:6192ENSG00000096968O60674Tyrosine-protein kinase JAK2gwas
RHOGHGNC:672ENSG00000177105P84095Rho-related GTP-binding protein RhoGgwas
SMAD3HGNC:6769ENSG00000166949P84022SMAD family member 3gwas
MATN2HGNC:6908ENSG00000132561O00339Matrilin-2gwas
NOVA1HGNC:7886ENSG00000139910P51513RNA-binding protein Nova-1gwas
PRKG1HGNC:9414ENSG00000185532Q13976cGMP-dependent protein kinase 1gwas
RAD50HGNC:9816ENSG00000113522Q92878DNA repair protein RAD50gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RORANuclear receptor ROR-alphaNuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5’-AGGTCA-3’ preceded by a short A-T-rich sequence.
SEMA6ASemaphorin-6ACell surface receptor for PLXNA2 that plays an important role in cell-cell signaling.
SOX4Transcription factor SOX-4Transcriptional activator that binds with high affinity to the T-cell enhancer motif 5’-AACAAAG-3’ motif.
STAT6Signal transducer and activator of transcription 6Carries out a dual function: signal transduction and activation of transcription.
KLF13Krueppel-like factor 13Transcription factor that activates expression from GC-rich minimal promoter regions, including genes in the cells of the erythroid lineage.
SHANK2SH3 and multiple ankyrin repeat domains protein 2Seems to be an adapter protein in the postsynaptic density (PSD) of excitatory synapses that interconnects receptors of the postsynaptic membrane including NMDA-type and metabotropic glutamate receptors, and the actin-based cytoskeleton.
CAPN14Calpain-14Calcium-regulated non-lysosomal thiol-protease.
EMSYBRCA2-interacting transcriptional repressor EMSYRegulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin.
SLC25A24Mitochondrial adenyl nucleotide antiporter SLC25A24Electroneutral antiporter that mediates the transport of adenyl nucleotides through the inner mitochondrial membrane.
CPNE4Copine-4Probable calcium-dependent phospholipid-binding protein that may play a role in calcium-mediated intracellular processes.
CCNYCyclin-YPositive regulatory subunit of the cyclin-dependent kinases CDK14/PFTK1 and CDK16.
ANKRD27Ankyrin repeat domain-containing protein 27May be a guanine exchange factor (GEF) for Rab21, Rab32 and Rab38 and regulate endosome dynamics.
TMEM182Transmembrane protein 182Negatively regulates myogenesis and skeletal muscle regeneration via its association with ITGB1.
JAZF1Juxtaposed with another zinc finger protein 1Acts as a transcriptional corepressor of orphan nuclear receptor NR2C2.
CLEC16AProtein CLEC16ARegulator of mitophagy through the upstream regulation of the RNF41/NRDP1-PRKN pathway.
NAMPTNicotinamide phosphoribosyltransferaseCatalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD.
DSG1Desmoglein-1Component of intercellular desmosome junctions.
WDR36WD repeat-containing protein 36Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit.
TSLPThymic stromal lymphopoietinCytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells.
URGCPUp-regulator of cell proliferationMay be involved in cell cycle progression through the regulation of cyclin D1 expression.
GALNT1Polypeptide N-acetylgalactosaminyltransferase 1Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.
LRRC32Transforming growth factor beta activator LRRC32Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space.
GPR12G-protein coupled receptor 12Brain-specific G protein-coupled receptor involved in regulating diverse physiological processes including neurite outgrowth, meiotic arrest, and lipid and carbohydrate metabolism.
HSF2BPHeat shock factor 2-binding proteinMeiotic recombination factor component of recombination bridges involved in meiotic double-strand break repair.
HSPA1BHeat shock 70 kDa protein 1BMolecular chaperone implicated in a wide variety of cellular processes, including protection of the proteome from stress, folding and transport of newly synthesized polypeptides, activation of proteolysis of misfolded proteins and the form…
JAK2Tyrosine-protein kinase JAK2Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications.
RHOGRho-related GTP-binding protein RhoGPlays a role in immunological synaptic F-actin density and architecture organization.
SMAD3SMAD family member 3Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases.
MATN2Matrilin-2Involved in matrix assembly.
NOVA1RNA-binding protein Nova-1RNA-binding protein which regulates alternative splicing of pre-mRNAs in the brain and spinal cord in a sequence-specific manner.
PRKG1cGMP-dependent protein kinase 1Serine/threonine protein kinase that acts as a key mediator of the nitric oxide (NO)/cGMP signaling pathway.
RAD50DNA repair protein RAD50Component of the MRN complex, which plays a central role in double-strand break (DSB) repair, DNA recombination, maintenance of telomere integrity and meiosis.

Protein-family classification

Druggable: 7 · Difficult: 8 · Unknown: 22 · Druggable fraction: 0.19

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Nuclear receptor110.4×0.655
Scaffold/PPI41.9×0.655
Kinase21.5×0.784
Other/Unknown221.1×0.784
Protease11.0×0.826
Transcription factor40.9×0.826
Enzyme (other)20.7×0.826
GPCR10.7×0.826

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RORANuclear receptoryesNucl_hrmn_rcpt_lig-bd, Znf_hrmn_rcpt, Nuclear_hrmn_rcpt
SEMA6AScaffold/PPInoSemap_dom, Plexin_repeat, WD40/YVTN_repeat-like_dom_sf
SOX4Transcription factornoHMG_box_dom, SOX-12/11/4, HMG_box_dom_sf
STAT6Transcription factornoSH2, STAT, p53-like_TF_DNA-bd_sf
DEXIOther/UnknownnoDexamethasone-induced
KLF13Transcription factornoZnf_C2H2_type, Znf_C2H2_sf
SHANK2Scaffold/PPInoSH3_domain, PDZ, SAM
CAPN14ProteaseyesPept_cys_AS, Peptidase_C2_calpain_cat, EF_hand_dom
EMSYOther/UnknownnoENT_dom, EMSY, ENT_dom-like_sf
SNHG32Other/Unknownno
SLC25A24Other/UnknownnoEF_hand_dom, MCP, GDC-like
CPNE4Other/UnknownnoC2_dom, VWF_A, Copine_C
CCNYOther/UnknownnoCyclin_N, Cyclin_Y, Cyclin-like_dom
ANKRD27Scaffold/PPInoAnkyrin_rpt, VPS9, Ankyrin_rpt-contain_sf
CCDC81Other/UnknownnoCCD81, HU-CCDC81, CCDC81_HU_dom_2
TMEM182Other/UnknownnoPMP22/EMP/MP20/Claudin, TMEM182
XKR6Other/UnknownnoXK-rel, XK-related_scramblase
JAZF1Transcription factornoZnf_C2H2_type, Znf_C2H2_sf, ZnF-Chromatin_assoc
CLEC16AOther/UnknownnoCLEC16A/TT9_N, CLEC16A/TT9, CLEC16A/TT9_C
NAMPTEnzyme (other)yes2.4.2.12Aldolase_TIM, Nicotinamide_PRibTrfase, Nicotinate_pribotase-like_C
DSG1Other/UnknownnoCadherin_Y-type_LIR, Cadherin-like_dom, Desmosomal_cadherin
WDR36Scaffold/PPInoWD40_rpt, WDR36/Utp21_C, WD40/YVTN_repeat-like_dom_sf
TSLPOther/UnknownnoTSLP, TSLP_sf
URGCPOther/UnknownnoGTP-bd, P-loop_NTPase, G_VLIG_dom
GALNT1Enzyme (other)yes2.4.1.41Ricin_B_lectin, Glyco_trans_2-like, Nucleotide-diphossugar_trans
LRRC32Other/UnknownnoLRRNT, Leu-rich_rpt, Leu-rich_rpt_typical-subtyp
MIR4675Other/Unknownno
GPR12GPCRyesGPCR_Rhodpsn, GPR12, GPR_3/6/12_orphan
HSF2BPOther/UnknownnoARM-like, ARM-type_fold, HSF2BP
HSPA1BOther/UnknownnoHsp_70_fam, Heat_shock_70_CS, HSP70_peptide-bd_sf
JAK2Kinaseyes2.7.10.2FERM_domain, Prot_kinase_dom, SH2
RHOGOther/UnknownnoSmall_GTPase, Small_GTPase_Rho, Small_GTP-bd
SMAD3Other/UnknownnoSMAD_dom, MAD_homology1_Dwarfin-type, SMAD_FHA_dom_sf
MATN2Other/UnknownnoEGF-type_Asp/Asn_hydroxyl_site, EGF, EGF-like_Ca-bd_dom
NOVA1Other/UnknownnoKH_dom, KH_dom_type_1, KH_dom_type_1_sf
PRKG1Kinaseyes2.7.11.12cNMP-bd_dom, Prot_kinase_dom, AGC-kinase_C
RAD50Other/UnknownnoRad50_eukaryotes, Zn_hook_RAD50, P-loop_NTPase

Expression context

Cohort genes with no expression data: 0.

30 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)37
unknown0

Top tissues across cohort

TissueCohort genes
calcaneal tendon5
cortical plate4
upper leg skin3
cerebellar hemisphere3
left testis3
lateral nuclear group of thalamus2
skin of hip2
ganglionic eminence2
granulocyte2
left ovary2
right ovary2
hindlimb stylopod muscle2
bronchial epithelial cell2
middle temporal gyrus2
lower esophagus mucosa2
pharyngeal mucosa2
ventricular zone2
left ventricle myocardium2
right testis2
buccal mucosa cell2

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
RORA284ubiquitousmarkerupper leg skin, lateral nuclear group of thalamus, skin of hip
SEMA6A266ubiquitousmarkerinferior vagus X ganglion, adrenal tissue, lateral globus pallidus
SOX4295ubiquitousmarkercortical plate, ganglionic eminence, embryo
STAT6292ubiquitousmarkergranulocyte, right ovary, left ovary
DEXI282ubiquitousyesapex of heart, hindlimb stylopod muscle, left adrenal gland cortex
KLF13169ubiquitousmarkerright hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
SHANK2240broadmarkerBrodmann (1909) area 23, bronchial epithelial cell, middle temporal gyrus
CAPN14116tissue_specificyeslower esophagus mucosa, pharyngeal mucosa, esophagus mucosa
EMSY260ubiquitousmarkerventricular zone, calcaneal tendon, cortical plate
SNHG32134ubiquitousmarkerleft ovary, ovary, right ovary
SLC25A24138ubiquitousyesrectum, duodenum, islet of Langerhans
CPNE4182broadmarkerlateral nuclear group of thalamus, left ventricle myocardium, endothelial cell
CCNY260ubiquitousmarkersperm, left testis, right testis
ANKRD27284ubiquitousmarkerchoroid plexus epithelium, amniotic fluid, upper leg skin
CCDC81173tissue_specificmarkerright uterine tube, bronchial epithelial cell, epithelium of bronchus
TMEM182205ubiquitousyescardiac muscle of right atrium, left ventricle myocardium, myocardium
XKR6167ubiquitousyesbuccal mucosa cell, primordial germ cell in gonad, middle temporal gyrus
JAZF1251ubiquitousmarkertrabecular bone tissue, cauda epididymis, right adrenal gland cortex
CLEC16A225ubiquitousmarkerleft testis, right testis, testis
NAMPT291ubiquitousmarkerblood, pericardium, mucosa of stomach
DSG1152tissue_specificmarkerupper arm skin, upper leg skin, skin of hip
WDR36249ubiquitousmarkercalcaneal tendon, tibialis anterior, deltoid
TSLP173ubiquitousmarkerepithelial cell of pancreas, gall bladder, cartilage tissue
URGCP274ubiquitousmarkerright adrenal gland cortex, right adrenal gland, left adrenal gland
GALNT1299ubiquitousmarkerbuccal mucosa cell, esophagus squamous epithelium, pharyngeal mucosa
LRRC32220ubiquitousmarkerright coronary artery, left coronary artery, right lung
MIR467537yescalcaneal tendon, gastrocnemius, kidney
GPR12102tissue_specificmarkercortical plate, ganglionic eminence, cerebellar hemisphere
HSF2BP124ubiquitousyesprimordial germ cell in gonad, left testis, testis
HSPA1B134ubiquitousmarkerlower esophagus mucosa, ventricular zone, gall bladder

Protein interactions among cohort

Intra-cohort edges: 11.

Hub genes (top 10 by interactor count)

SymbolInteractor count
SMAD36,440
JAK26,197
NAMPT3,509
STAT63,345
WDR363,290
SOX42,846
RAD502,552
CLEC16A2,028
ANKRD271,937
SHANK21,920

Intra-cohort edges

ABSources
ANKRD27CAPN14string_interaction
CAPN14DSG1string_interaction
CAPN14EMSYstring_interaction
CAPN14LRRC32string_interaction
CAPN14TSLPstring_interaction
CAPN14WDR36string_interaction
CLEC16ADEXIstring_interaction
EMSYLRRC32string_interaction
EMSYWDR36string_interaction
JAK2STAT6string_interaction
LRRC32WDR36string_interaction

Structural data

PDB: 21 · AlphaFold-only: 14 · No structure: 2

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
JAK2O60674164
NAMPTP4349084
PRKG1Q1397626
SMAD3P8402212
STAT6P422267
LRRC32Q143926
RHOGP840956
RAD50Q928786
TSLPQ969D95
HSPA1BP0DMV95
ANKRD27Q96NW44
HSF2BPO750314
RORAP353983
EMSYQ7Z5893
SLC25A24Q6NUK13
WDR36Q8NI363
NOVA1P515133
SHANK2Q9UPX82
CCNYQ8ND762
SEMA6AQ9H2E61
GPR12P477751

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
GALNT1Q1047291.66
CPNE4Q96A2387.42
TMEM182Q6ZP8087.24
CAPN14A8MX7686.02
URGCPQ8TCY976.78
MATN2O0033975.94
CLEC16AQ2KHT372.17
CCDC81Q6ZN8471.04
JAZF1Q86VZ670.25
DEXIO9542469.88
XKR6Q5GH7364.85
DSG1Q0241362.93
KLF13Q9Y2Y958.91
SOX4Q0694555.71

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 211. Enrichment computed across 37 evidence-associated genes (19 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 19 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)323.1×0.029STAT6, KLF13, RAD50
Signaling by Interleukins413.5×0.029RORA, STAT6, JAK2, SMAD3
Interleukin-4 and Interleukin-13 signaling316.2×0.054RORA, STAT6, JAK2
Cytokine Signaling in Immune system48.6×0.054RORA, STAT6, JAK2, SMAD3
R-HSA-400253236.4×0.057RORA, NAMPT
STAT6-mediated induction of chemokines1200.3×0.106STAT6
Loss of Function of SMAD4 in Cancer1200.3×0.106SMAD3
SMAD4 MH2 Domain Mutants in Cancer1200.3×0.106SMAD3
SMAD2/3 MH2 Domain Mutants in Cancer1200.3×0.106SMAD3
R-HSA-1972641150.3×0.106NAMPT
Loss of Function of TGFBR1 in Cancer1120.2×0.106SMAD3
RUNX3 regulates BCL2L11 (BIM) transcription1120.2×0.106SMAD3
Loss of Function of SMAD2/3 in Cancer1100.2×0.106SMAD3
Signaling by TGF-beta Receptor Complex in Cancer1100.2×0.106SMAD3
SMAD2/3 Phosphorylation Motif Mutants in Cancer1100.2×0.106SMAD3
TGFBR1 KD Mutants in Cancer1100.2×0.106SMAD3
Sensing of DNA Double Strand Breaks1100.2×0.106RAD50
RUNX3 regulates CDKN1A transcription185.9×0.106SMAD3
Erythropoietin activates Phospholipase C gamma (PLCG)185.9×0.106JAK2
Erythropoietin activates STAT5185.9×0.106JAK2
Interleukin-6 family signaling175.1×0.106JAK2
IFNG signaling activates MAPKs175.1×0.106JAK2
Interleukin-23 signaling166.8×0.106JAK2
Maturation of protein 3a166.8×0.106GALNT1
MAPK1 (ERK2) activation160.1×0.106JAK2
Signaling by KIT in disease160.1×0.106JAK2
MAPK3 (ERK1) activation154.6×0.106JAK2
STING mediated induction of host immune responses154.6×0.106STAT6
Signaling by Leptin154.6×0.106JAK2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 32 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
growth hormone receptor signaling pathway via JAK-STAT295.8×0.040STAT6, JAK2
cell surface receptor signaling pathway via JAK-STAT327.2×0.040STAT6, TSLP, JAK2
positive regulation of circadian rhythm275.2×0.044RORA, PRKG1
myotube cell development involved in skeletal muscle regeneration1526.6×0.054TMEM182
nuclear receptor-mediated mineralocorticoid signaling pathway1526.6×0.054JAK2
symbiont-induced defense-related programmed cell death1526.6×0.054JAK2
negative regulation of lung blood pressure1526.6×0.054SMAD3
regulation of mast cell proliferation1526.6×0.054STAT6
interleukin-35-mediated signaling pathway1526.6×0.054JAK2
positive regulation of chemokine (C-C motif) ligand 1 production1526.6×0.054TSLP
negative regulation of cell adhesion involved in sprouting angiogenesis1526.6×0.054SEMA6A
regulation of miRNA transcription1526.6×0.054SMAD3
negative regulation of myoblast differentiation239.0×0.054SOX4, TMEM182
cytokine-mediated signaling pathway312.2×0.054STAT6, TSLP, JAK2
protein stabilization48.4×0.054SOX4, DSG1, HSPA1B, SMAD3
regulation of mitotic recombination1263.3×0.055RAD50
negative regulation of inositol phosphate biosynthetic process1263.3×0.055PRKG1
dendrite regeneration1263.3×0.055MATN2
positive regulation of transforming growth factor beta3 production1263.3×0.055SMAD3
negative regulation of SNARE complex assembly1263.3×0.055ANKRD27
establishment of protein localization to extracellular region1263.3×0.055LRRC32
mammary gland morphogenesis1263.3×0.055STAT6
response to interleukin-121263.3×0.055JAK2
positive regulation of growth factor dependent skeletal muscle satellite cell proliferation1263.3×0.055JAK2
regulation of postsynapse to nucleus signaling pathway1263.3×0.055JAK2
positive regulation of nitric oxide biosynthetic process228.5×0.055JAK2, SMAD3
positive regulation of protein import into nucleus226.3×0.055JAK2, SMAD3
positive regulation of SMAD protein signal transduction223.9×0.055JAK2, SMAD3
positive regulation of cell population proliferation55.3×0.055SOX4, SHANK2, NAMPT, TSLP, RHOG
glial cell development1175.5×0.057SOX4

Therapeutics

Drugs indicated for this disease

0 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
BenralizumabPhase 3 (in late-stage trials)
BudesonidePhase 3 (in late-stage trials)
CendakimabPhase 3 (in late-stage trials)
DupilumabPhase 3 (in late-stage trials)
FluticasonePhase 3 (in late-stage trials)
Fluticasone PropionatePhase 3 (in late-stage trials)
MontelukastPhase 3 (in late-stage trials)
ReslizumabPhase 3 (in late-stage trials)
TezepelumabPhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Barzolvolimab, Bethanechol, Esomeprazole, Etrasimod, Famotidine, Infliximab, Lansoprazole, Lirentelimab, Loratadine, Mepolizumab, Mesalamine, Mometasone Furoate, Omalizumab, Sodium Chloride, Timapiprant.

Drug target analysis

Approved (phase 4): 5 · Phase ≥3: 6 · Phased (≥1): 9 · Undrugged: 28

Druggability breadth: 15 of 37 evidence-associated genes (41%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
RORATRETINOIN
STAT6THIORIDAZINE HYDROCHLORIDE
JAK2FEDRATINIB
SMAD3FLUORESCEIN
PRKG1FEDRATINIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
JAK21004
PRKG1154
STAT6114
NAMPT43
RORA24
CCNY22
SMAD324
DSG112
RAD5012
SEMA6A00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
TRETINOIN4RORA
THIORIDAZINE HYDROCHLORIDE4STAT6
DOXORUBICIN HYDROCHLORIDE4STAT6
AMSACRINE4STAT6
ADENOSINE4STAT6
AMANTADINE4STAT6
BISACODYL4STAT6
FEDRATINIB4JAK2, PRKG1
RUXOLITINIB4JAK2
TOFACITINIB4JAK2
UPADACITINIB4JAK2
MOMELOTINIB4JAK2
PONATINIB4JAK2
AXITINIB4JAK2
NICLOSAMIDE4JAK2
RUXOLITINIB PHOSPHATE4JAK2
INFIGRATINIB PHOSPHATE4JAK2
INFIGRATINIB4JAK2
ENTRECTINIB4JAK2
DABRAFENIB4JAK2
PACRITINIB4JAK2, PRKG1
TOFACITINIB CITRATE4JAK2
BARICITINIB4JAK2
CERITINIB4JAK2
BOSUTINIB4JAK2
PEFICITINIB4JAK2
LORLATINIB4JAK2
FILGOTINIB4JAK2
BRIGATINIB4JAK2
ABROCITINIB4JAK2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 4.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
JAK22,018Binding:1911, Functional:51, ADMET:48, Unclassified:4, Toxicity:4
PRKG1356Binding:355, Functional:1
NAMPT299Binding:299
CCNY196Binding:196
RORA115Binding:111, Functional:3, Unclassified:1
STAT681Binding:77, Functional:4
SMAD324Binding:18, Functional:6
TSLP12Binding:12
DSG18Binding:8
RAD507Binding:7
GPR124Binding:2, Functional:2
HSPA1B3Binding:3
CPNE41Binding:1
WDR361Binding:1
GALNT11Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
NAMPT2.4.2.12nicotinamide phosphoribosyltransferase
GALNT12.4.1.41polypeptide N-acetylgalactosaminyltransferase
JAK22.7.10.2non-specific protein-tyrosine kinase
PRKG12.7.11.12cGMP-dependent protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
RORA115
CCNY196
NAMPT299
JAK22,018
PRKG1356

Pharmacogenomics

Cohort genes with a PharmGKB record: 36; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
TRETINOIN4RORA
THIORIDAZINE HYDROCHLORIDE4STAT6
DOXORUBICIN HYDROCHLORIDE4STAT6
AMSACRINE4STAT6
ADENOSINE4STAT6
AMANTADINE4STAT6
BISACODYL4STAT6
FEDRATINIB4JAK2, PRKG1
RUXOLITINIB4JAK2
TOFACITINIB4JAK2
UPADACITINIB4JAK2
MOMELOTINIB4JAK2
PONATINIB4JAK2
AXITINIB4JAK2
NICLOSAMIDE4JAK2
RUXOLITINIB PHOSPHATE4JAK2
INFIGRATINIB PHOSPHATE4JAK2
INFIGRATINIB4JAK2
ENTRECTINIB4JAK2
DABRAFENIB4JAK2
PACRITINIB4JAK2, PRKG1
TOFACITINIB CITRATE4JAK2
BARICITINIB4JAK2
CERITINIB4JAK2
BOSUTINIB4JAK2
PEFICITINIB4JAK2
LORLATINIB4JAK2
FILGOTINIB4JAK2
BRIGATINIB4JAK2
ABROCITINIB4JAK2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)5RORA, STAT6, JAK2, SMAD3, PRKG1
BPhased (≥1) drug, not yet approved4CCNY, NAMPT, DSG1, RAD50
CDruggable family + PDB, no drug1GPR12
DDruggable family + AlphaFold only, no drug2CAPN14, GALNT1
EDifficult family or no structure, no drug25SEMA6A, SOX4, DEXI, KLF13, SHANK2, EMSY, SNHG32, SLC25A24, CPNE4, ANKRD27 (+15 more)

Undrugged target profiles

28 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
CAPN140DSG1
SEMA6A0—
SOX40—
DEXI0—
KLF130—
SHANK20—
EMSY0—
SNHG320—
SLC25A240—
CPNE41—
ANKRD270—
CCDC810—
TMEM1820—
XKR60—
JAZF10—
CLEC16A0—
WDR361—
TSLP12—
URGCP0—
GALNT11—
LRRC320—
MIR46750—
GPR124—
HSF2BP0—
HSPA1B3—
RHOG0—
MATN20—
NOVA10—

Clinical trials & evidence

Clinical trials

Clinical trials: 207.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified122
PHASE233
PHASE319
PHASE410
PHASE110
PHASE2/PHASE35
PHASE1/PHASE25
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04149470PHASE4ACTIVE_NOT_RECRUITINGProton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
NCT06352073PHASE4ACTIVE_NOT_RECRUITINGDupilumab for Eosinophilic Esophagitis With Severe Strictures
NCT06665971PHASE4RECRUITINGEffect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT01404832PHASE4TERMINATEDThe Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors
NCT01846962PHASE4COMPLETEDDietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis
NCT02019758PHASE4COMPLETEDBudesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
NCT02371941PHASE4COMPLETEDOral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis
NCT03781596PHASE4UNKNOWNEoE RCT Fluticasone and Omeprazole vs Fluticasone Alone
NCT05247866PHASE4COMPLETEDEfficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
NCT05444543PHASE4COMPLETEDCycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
NCT05583227PHASE3ACTIVE_NOT_RECRUITINGEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
NCT06596252PHASE3RECRUITINGOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT07112378PHASE3RECRUITINGA Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT00266578PHASE3COMPLETEDA Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders
NCT00538434PHASE2/PHASE3COMPLETEDEfficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
NCT00635089PHASE3COMPLETEDOpen-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
NCT00728481PHASE2/PHASE3COMPLETEDThe Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis
NCT01702701PHASE3WITHDRAWNEosinophilic Esophagitis Treatment: Montelukast vs Fluticasone
NCT02434029PHASE3COMPLETEDBudesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
NCT02493335PHASE3COMPLETEDMaintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis
NCT02605837PHASE3COMPLETEDA Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
NCT02610816PHASE2/PHASE3COMPLETEDEosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
NCT02736409PHASE3COMPLETEDAn Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
NCT02778867PHASE2/PHASE3COMPLETEDSOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
NCT03245840PHASE3TERMINATEDContinuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
NCT03633617PHASE3COMPLETEDStudy to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
NCT04281108PHASE3COMPLETEDEfficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)
NCT04322708PHASE2/PHASE3COMPLETEDA Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
NCT04394351PHASE3COMPLETEDStudy to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
NCT04543409PHASE3TERMINATEDA Study of Benralizumab in Patients With Eosinophilic Esophagitis
NCT04753697PHASE3COMPLETEDA Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935PHASE3COMPLETEDSafety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT05083312PHASE3COMPLETEDEfficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
NCT05634746PHASE3COMPLETED24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
NCT05485155PHASE2RECRUITINGZemaira Eosinophilic Esophagitis Pilot Study
NCT05608681PHASE1/PHASE2RECRUITINGA Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
NCT06598462PHASE2ACTIVE_NOT_RECRUITINGA Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
NCT06705387PHASE2RECRUITINGDupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
NCT06851559PHASE2RECRUITINGA Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT07588568PHASE2NOT_YET_RECRUITINGA Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DUPILUMAB45
BUDESONIDE43
FLUTICASONE PROPIONATE42
MEPOLIZUMAB42
RESLIZUMAB42
BECLOMETHASONE DIPROPIONATE41
BENRALIZUMAB41
BETHANECHOL41
CROMOLYN SODIUM41
DEXLANSOPRAZOLE41
ETRASIMOD41
FAMOTIDINE41
LORATADINE41
MESALAMINE41
MOMETASONE FUROATE41
OMEPRAZOLE41
SUCRALFATE41
TEZEPELUMAB41
VONOPRAZAN41
XYLOSE41
FLUTICASONE37
CENDAKIMAB33
BARIUM31
BARZOLVOLIMAB31
HONEY31
LIRENTELIMAB31
TECHNETIUM TC-99M31
TIMAPIPRANT31
IRL-20110421
OMILANCOR21

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 74

This page pulls from 74 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergardgenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncicd10cmintactinterpromeddramedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot